MarketPulse

chronic spontaneous urticaria

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Novartis

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.
NVSchronic spontaneous urticariaimmunology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Septerna's SEP-631 Shows Promise in Mast Cell Disease Treatment

Septerna reports positive Phase 1 data for SEP-631, an experimental oral treatment for mast cell-driven diseases, with plans for Phase 2b development beginning late 2026.
SEPNchronic spontaneous urticariaoral small-molecule
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria